[PDF][PDF] The Safety Profile of Fenebrutinib in Patients With Multiple Sclerosis Is Consistent With Those in Previously Studied Autoimmune Indications
The Safety Profile of Fenebrutinib in Patients With Multiple Sclerosis Is Consistent With Those In
Previously Studied Autoimmune Page 1 The Safety Profile of Fenebrutinib in Patients With …
Previously Studied Autoimmune Page 1 The Safety Profile of Fenebrutinib in Patients With …
The Safety Profile of Fenebrutinib in Patients with Multiple Sclerosis Is Consistent with Those in Previously Studied Autoimmune Indications (P9-6.012)
Objective: To compare the safety and tolerability of fenebrutinib in people with multiple
sclerosis (MS) and those with autoimmune indications (AIs). Background: Fenebrutinib is a …
sclerosis (MS) and those with autoimmune indications (AIs). Background: Fenebrutinib is a …
The safety of fenebrutinib in a large population of patients with diverse autoimmune indications supports investigation in multiple sclerosis (MS)(4564)
Objective: To analyze the large fenebrutinib safety database of prior autoimmune
randomized clinical trials (RCTs) and open-label extensions (OLEs). Background …
randomized clinical trials (RCTs) and open-label extensions (OLEs). Background …
[PDF][PDF] The safety of fenebrutinib in a large population of patients with diverse autoimmune conditions supports investigation in multiple sclerosis
J Oh, S Cohen, D Isenberg, M Maurer… - AAN virtual …, 2021 - cuba.dialogoroche.com
Background: Overall, fenebrutinib has been well tolerated, with mostly non-serious AEs, mild-
to-moderate in naturea aRoche data on file; bMay affect the efficacy of fenebrutinib, or lead …
to-moderate in naturea aRoche data on file; bMay affect the efficacy of fenebrutinib, or lead …
177. Fenebrutinib Maintains Low Disease Activity in Relapsing Multiple Sclerosis: Results from the FENopta Trial Open-label Extension
Background/Objective (s) Fenebrutinib (FEN) is a potent, highly selective, noncovalent,
reversible Bruton's tyrosine kinase inhibitor. In the 12-week, placebo (PBO)–controlled …
reversible Bruton's tyrosine kinase inhibitor. In the 12-week, placebo (PBO)–controlled …
[PDF][PDF] Fenebrutinib reduces disease activity in a mouse model of inflammatory multiple sclerosis, which is associated with reduced microglial activation
MS Weber, C Harp, A Goodyear… - Congress of the …, 2021 - medically.gene.com
1Institute of Neuropathology, University Medical Center, Göttingen, Germany; 2Department
of Neurology, University Medical Center, Göttingen, Germany; 3Genentech, Inc., South San …
of Neurology, University Medical Center, Göttingen, Germany; 3Genentech, Inc., South San …
[HTML][HTML] Multiple Sclerosis Disability Suppression Observed in New Fenebrutinib Phase 2 Data
M Meglio - neurologylive.com
New data expected to be presented at the 40th Congress of the European Committee for
Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, show …
Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, show …
[PDF][PDF] Efficacy and safety of fenebrutinib, a noncovalent, reversible BTK inhibitor, in ms: primary results of a phase II trial
Efficacy and Safety of Fenebrutinib, a Noncovalent, Reversible BTK inhibitor, in MS: Primary
Results of a Phase 2 Trial Page 1 Efficacy and Safety of Fenebrutinib, a Noncovalent, Reversible …
Results of a Phase 2 Trial Page 1 Efficacy and Safety of Fenebrutinib, a Noncovalent, Reversible …
Safety of Evobrutinib in Patients With Relapsing Multiple Sclerosis is Maintained in a Long-term Open-label Extension of a Phase II Study (4131)
X Montalban, DL Arnold, MS Weber, I Staikov… - Neurology, 2021 - AAN Enterprises
Objective: We report long-term safety data from an ongoing open-label extension (OLE) in
patients treated≥ 60 OLE weeks or discontinuing early. Background: In a 48-week Phase II …
patients treated≥ 60 OLE weeks or discontinuing early. Background: In a 48-week Phase II …
Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis (P8-6.015)
Objective: To report the integrated safety profile of remibrutinib using pooled data from
completed phase 2 clinical trials in chronic spontaneous urticaria (CSU), Sjögren syndrome …
completed phase 2 clinical trials in chronic spontaneous urticaria (CSU), Sjögren syndrome …